By Josh White
Date: Monday 23 Sep 2024
(Sharecast News) - Oxford Biomedica, a prominent gene and cell therapy company, reported significant revenue growth alongside strategic advancements in its interim results on Monday.
By Josh White
Date: Thursday 08 Aug 2024
(Sharecast News) - Cell and gene therapy contract development and manufacturing organisation Oxford Biomedica reported a strong first-half trading performance in an update on Thursday, with revenue expected to reach £50m.
By Josh White
Date: Wednesday 17 Jul 2024
(Sharecast News) - Cell and gene therapy contract development and manufacturing organisation (CDMO) Oxford Biomedica announced the appointment of Lucinda 'Lucy' Crabtree as its new chief financial officer and a member of the board on Wednesday.
Currency | UK Pounds |
Share Price | 320.00p |
Change Today | 16.50p |
% Change | 5.44 % |
52 Week High | 445.00p |
52 Week Low | 232.50p |
Volume | 159,159 |
Shares Issued | 106.00m |
Market Cap | £339.20m |
Beta | 0.01 |
RiskGrade | 125 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 3 |
Buy | 2 |
Neutral | 4 |
Sell | 0 |
Strong Sell | 0 |
Total | 9 |
No dividends found |
Time | Volume / Share Price |
16:26 | 1 @ 321.00p |
16:17 | 170 @ 320.50p |
16:17 | 2 @ 322.00p |
16:17 | 184 @ 321.00p |
16:13 | 29 @ 321.50p |
Chair | Roch Doliveux |
CEO | Frank Mathias |
CFO | Lucinda (Lucy) Crabtree |
You are here: research